An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-117 Compared to AD-117A in Healthy Adult Volunteers Under Fed State Conditions
An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-117 Compared to AD-117A in Healthy Adult Volunteers Under Fed State Conditions
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-117 in healthy subjects.
Inclusion Criteria:
Exclusion Criteria:
dskim@addpharma.co.kr+82-31-891-5572